Search

for
Search:

Did you mean Cardiovascular Events?

GlossaryCardiovascular Events

occur when heart or blood vessels experience sudden issues

Cardiovascular Events, also known as Cardiovascular Incidents or Cardiac Events, refer to any occurrences that affect the heart or blood vessels, such as heart attacks, strokes, or sudden cardiac arrests. These events are critical medical conditions that often require immediate attention and can result from underlying issues like atherosclerosis, hypertension, or arrhythmias.

Related Terms

Sort by

Research

30 / 1000+ results

research 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events

September 2023 in “Journal of the American Academy of Dermatology”

Ixekizumab is safe for long-term use with low rates of major heart-related events.

research Hidradenitis suppurativa and major adverse cardiac events: A systematic review and meta-analysis

7 citations , October 2020 in “Journal of The American Academy of Dermatology”

People with hidradenitis suppurativa have a higher risk of heart attacks and strokes.

Response to the Role of Patient and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

research Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”

August 2025 in “Journal of Cosmetic Dermatology”

Oral minoxidil users, especially for hypertension, may risk heart issues, and better monitoring guidelines are needed for alopecia patients.

research Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review

March 2025 in “Journal of Clinical Medicine”

Low-dose oral minoxidil effectively treats alopecia but can cause side effects like excess hair growth and fluid retention.

research Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)

March 2026 in “Life”

Oral minoxidil may have more cardiovascular risks than topical minoxidil.

research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW

December 2025 in “International Journal of Innovative Technologies in Social Science”

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

6 citations , February 2023 in “Advances in Therapy”

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

research Reporting on Adverse Clinical Events

October 2008 in “Clin-alert”

Certain medications can reduce mortality risk in COPD patients, but others can increase risks of cardiovascular issues, postoperative delirium, and other adverse effects.

research There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses

2 citations , January 2022 in “Skin appendage disorders”

Low-dose oral minoxidil effectively promotes hair growth but has associated risks.

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months in Patients with Alopecia Areata from the Allegro Clinical Trial Program

research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program

July 2025 in “SKIN The Journal of Cutaneous Medicine”

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?

April 2022

Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.

research Reporting on Adverse Clinical Events

November 2010 in “Clin-Alert”

Monitoring for adverse effects in clinical treatments is crucial.

Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-Days Post-Discharge: A Population-Based Cohort Study of Older Adults

research Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults

August 2022 in “medRxiv (Cold Spring Harbor Laboratory)”

Certain groups of medications given when leaving the hospital are linked to a higher risk of negative drug reactions within 30 days, especially in older adults with respiratory issues.

The Role of Patient and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

research The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

December 2024 in “Journal of Cosmetic Dermatology”

Oral minoxidil rarely causes pericardial effusion, especially at low doses.

research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression

75 citations , January 2014 in “Korean Journal of Urology”

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

5α-Reductase Inhibitor Therapy: Should Physicians Be Concerned With Persistent Diminished Libido, Erectile Dysfunction, and Depression in a Subset of Patients?

research 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients?

October 2010 in “Journal of Men's Health”

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

research A Retrospective Study on the Safety of Systemic Minoxidil for Hair Loss in the Older Population

November 2024 in “International Society of Hair Restoration Surgery”

Systemic minoxidil is generally safe for older adults, but caution is needed for those with heart risks.

research Minoxidil

October 2015 in “Elsevier eBooks”

Minoxidil is effective for hair growth and safe for long-term use.

research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study

July 2025 in “Journal of Investigative Dermatology”

Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.

research Cardiovascular Toxicities of Androgen Deprivation Therapy

45 citations , April 2021 in “Current Treatment Options in Oncology”

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.

research Cardiovascular effects of hormone therapy for prostate cancer

18 citations , July 2015 in “Drug Healthcare and Patient Safety”

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

research Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?

418 citations , June 2003 in “Endocrine Reviews”

While PCOS might increase the risk of heart disease, there's not strong evidence to prove it causes earlier heart problems.

research Estimation of biological heart age using cardiovascular magnetic resonance radiomics

30 citations , July 2022 in “Scientific Reports”

Obesity and lifestyle strongly affect heart aging.

Effects of Reducing Tissue Iron Deposits on Cardiovascular Risk Factors in Patients with Functional Ovarian Hyperandrogenism

research Efectos de la disminución de los depósitos tisulares de hierro sobre los factores de riesgo cardiovascular en pacientes con hiperandrogenismo ovárico funcional

January 2023 in “e_Buah”

Reducing iron levels didn't improve heart health or metabolism in women with certain ovarian issues.

research Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome

200 citations , October 2009 in “European journal of endocrinology”

Metformin helps manage polycystic ovary syndrome by improving insulin resistance and ovulation, but more research is needed on its full effects.

Search

for
Search:

Related Terms

Research

research 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events

research Hidradenitis suppurativa and major adverse cardiac events: A systematic review and meta-analysis

research Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”

research Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review

research Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)

research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW

research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

research Reporting on Adverse Clinical Events

research There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program

research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?

research Reporting on Adverse Clinical Events

research Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults

research The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression

research 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients?

research A Retrospective Study on the Safety of Systemic Minoxidil for Hair Loss in the Older Population

research Minoxidil

research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study

research Cardiovascular Toxicities of Androgen Deprivation Therapy

research Cardiovascular effects of hormone therapy for prostate cancer

research Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?

research Estimation of biological heart age using cardiovascular magnetic resonance radiomics

research Efectos de la disminución de los depósitos tisulares de hierro sobre los factores de riesgo cardiovascular en pacientes con hiperandrogenismo ovárico funcional

research Compounded Testosterone Troches TO OPTIMIZE HEALTH AND THE TESTOSTERONE CONTROVERSY.

research Hormonal, Medical, and Nonsurgical Aspects of Gender Affirmation

research EFFICACY AND SAFETY OF LOW-DOSE ORAL MINOXIDIL IN THE TREATMENT OF ANDROGENETIC ALOPECIA – A LITERATURE REVIEW

research Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome